Department of Vascular Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Division of Vascular and Endovascular Surgery, Department of Surgery, University of Washington and Puget Sound VA Health Care System, Seattle, WA.
J Vasc Surg. 2022 Oct;76(4):1089-1098.e8. doi: 10.1016/j.jvs.2022.03.005. Epub 2022 Mar 18.
Iliac branch devices (IBDs) have been used in the treatment of aortoiliac and isolated iliac artery aneurysms. The aim of this systematic review and meta-analysis was to investigate the clinical effectiveness and safety of IBDs.
A systematic review of the literature was conducted by identifying studies in the Medline, EMBASE, and Cochrane databases regarding the outcomes of IBDs in aortoiliac or isolated iliac artery aneurysms between May 2006 and December 2020. Individual studies were evaluated for the following major outcomes: technical success, 30-day mortality, primary patency, endoleak, reintervention, and rates of pelvic ischemia. Furthermore, subgroup meta-analyses were performed to compare the pelvic ischemic events in patients with bilateral IBDs, unilateral IBDs, and bilateral internal iliac artery (IIA) embolization/coverage.
Forty-five studies with a total of 2736 patients undergoing unilateral or bilateral IBDs met inclusion criteria and were included in the analysis. The pooled technical success rate of IBDs was 98.0% (confidence interval [CI]: 97.3%-98.7%). After IBD treatment, the 30-day mortality rate was 0.4% (CI: 0.07%-0.70%); 30-day patency was 98.4% (CI: 97.7%-99.0%); buttock claudication developed in 1.84% (CI: 1.26%-2.41%); and endoleak occurred in 11.9% (CI: 9.2%-14.7%) and reintervention in 7.6% (CI: 5.65%-9.58%). Furthermore, in patients with bilateral iliac artery involvement, the pooled estimate rates of buttock claudication were 0.7% in the bilateral IBD group, 7.9% in unilateral IBD with contralateral IIA embolization patients, and 33.8% in bilateral IIA embolization/coverage patients, which were statistically significant among the three groups. Sexual dysfunction was 5.0% in the bilateral IIA occlusion group, which was significantly higher than that in IBD groups.
The utilization of IBDs in the treatment of aortoiliac or isolated iliac artery aneurysms is associated with high technical success rates as well as low incidences of pelvic ischemia. The risk of postoperative buttock claudication can be further decreased with both IIA preservation if patients are anatomically suitable for bilateral IBDs.
髂分支装置(IBD)已用于治疗主髂和孤立髂动脉瘤。本系统评价和荟萃分析旨在研究 IBD 的临床效果和安全性。
通过在 Medline、EMBASE 和 Cochrane 数据库中检索 2006 年 5 月至 2020 年 12 月期间关于 IBD 在主髂或孤立髂动脉瘤中的结果的研究,进行系统的文献回顾。对个别研究进行了以下主要结果的评估:技术成功率、30 天死亡率、一期通畅率、内漏、再介入和盆腔缺血发生率。此外,还进行了亚组荟萃分析,以比较双侧 IBD 患者、单侧 IBD 患者和双侧髂内动脉(IIA)栓塞/覆盖患者的盆腔缺血事件。
45 项研究共纳入 2736 例接受单侧或双侧 IBD 的患者,符合纳入标准并纳入分析。IBD 的总体技术成功率为 98.0%(置信区间[CI]:97.3%-98.7%)。IBD 治疗后 30 天死亡率为 0.4%(CI:0.07%-0.70%);30 天通畅率为 98.4%(CI:97.7%-99.0%);臀肌跛行发生率为 1.84%(CI:1.26%-2.41%);内漏发生率为 11.9%(CI:9.2%-14.7%),再介入率为 7.6%(CI:5.65%-9.58%)。此外,在双侧髂动脉受累的患者中,双侧 IBD 组的臀肌跛行发生率为 0.7%,单侧 IBD 对侧 IIA 栓塞患者为 7.9%,双侧 IIA 栓塞/覆盖患者为 33.8%,三组间差异有统计学意义。双侧 IIA 闭塞组的性功能障碍发生率为 5.0%,明显高于 IBD 组。
在主髂或孤立髂动脉瘤的治疗中使用 IBD 与高技术成功率以及低盆腔缺血发生率相关。如果患者的解剖结构适合双侧 IBD,保留 IIA 可进一步降低术后臀肌跛行的风险。